by TractManager | Mar 15, 2023 | Emerging Technology Report
Trofinetide (Daybue) is an oral synthetic glypromate analog indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.If you have a Hayes login, click here to view the full report on the Knowledge Center.
by TractManager | Mar 10, 2023 | Health Technology Assessment
Focus of the Report: The focus of this Health Technology Assessment is to evaluate the effectiveness and safety of repetitive transcranial magnetic stimulation (rTMS) for the treatment of adult patients with bipolar disorder (BD).Technology Description: Transcranial...
by TractManager | Mar 8, 2023 | Emerging Technology Report
Omaveloxolone is an oral drug that activates nuclear factor erythroid 2-related factor 2 (Nrf2). It is intended for treatment of Friedreich ataxia (FA), a rare hereditary neurodegenerative disorder that is driven by mitochondrial dysfunction and impaired Nrf2...
by TractManager | Mar 8, 2023 | Molecular Test Assessment
This report evaluates the clinical validity and clinical utility of the ThyroSeq v3 Genomic Classifier (University of Pittsburgh Medical Center and Sonic Healthcare USA).If you have a Hayes login, click here to view the full report on the Knowledge Center.
by TractManager | Mar 6, 2023 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the MyoPro orthosis (Myomo Inc.) for upper extremity paralysis/paresis after stroke to reduce motor impairment.If...
Recent Comments